Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized placebo-controlled study of ALVAC-HIV vCP1452 prime-boost immunization in chronic HIV infection
2004-001525-21Phase 2Active
- Sponsor
- ORVACS
- Start
- May 2005
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of ALVAC-HIV vCP1452 in human immunodeficiency virus infection (HIV) (3 arms), sponsored by ORVACS. Primary endpoint: Change from baseline in frequency of HIV-specific peripheral blood mononuclear cells at week 24. Started May 2005; status: active.
02
Drugs
ALVAC-HIV vCP1452
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2004-001525-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001525-21.